Core Points - Wanfu Biological announced a stock repurchase plan, with a total of 13,000 shares repurchased, representing 0.0028% of the company's total share capital [2] Summary by Category Company Actions - The company has implemented a stock repurchase through a dedicated account, utilizing centralized bidding transactions [2] - The repurchase is set to continue until September 30, 2025 [2] Financial Impact - The total number of shares repurchased is 13,000, which is a small fraction of the overall share capital [2] - The repurchase represents 0.0028% of the company's total equity [2]

Core Viewpoint - Wanfu Biological (300482.SZ) has conducted a share buyback, acquiring a total of 13,000 shares, which represents 0.0028% of the company's total share capital, in compliance with its buyback plan and relevant regulations [1] Summary by Categories - **Share Buyback Details** - The company implemented the buyback through a special account for stock repurchase via centralized bidding [1] - The highest transaction price for the repurchased shares was 21.21 yuan per share, with the lowest also being 21.21 yuan per share [1] - The total amount spent on the buyback was 275,729.00 yuan, excluding transaction fees [1]

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在回购期间每个月的前三个交易日内 披露截至上月末的回购进展情况，现将具体情况公告如下： 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开的第五届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金以集中竞价交易方式回购公司已发行的人民币普通股股 份，用于员工持股计划和股权激励。本次用于回购股份的资金总额不低于人民币 3,000 万元且不超过人民币 6,000 万元（均包含本数），回购价格不超过人民币 34.66 元/股（含），回购实施期限自公司董事会审议通过本次回购方案之日起 6 个月内。具体内容详见公司刊登在中国证监会指定创业板信息披露网站上的相关 公告。 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、回购公司股份的进展情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前三个交 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-057 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： | 证券代码：300482 | | 证券简称：万孚生物 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 债券代码：123064 | | 债券简称：万孚转债 | | | | | | | | 转股价格：人民币 | | 27.00 元/股 | | | | | | | | 转股时间：2021 | 年 3 | 月 8 | 日至 | 2026 | 年 | 8 月 | 31 | 日 | 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所可转换公司 债券业务实施细则》的有关规定，广州万孚生物技术股份有限公司（以下简称"公 司"）现将 2025 年第三季度可转换公司债券（以下简称"可转债"）转股及公司股 份变动的情况公告如下： 一、 ...

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 29 yuan [2][8]. Core Views - The company's performance is under pressure in the short term, with a significant decline in revenue and profit. The total revenue for the first half of 2025 was 1.246 billion yuan, down 20.92%, and the net profit attributable to shareholders was 189 million yuan, down 46.82% [2][3]. - The company is making steady progress in expanding its overseas business, which is expected to help mitigate domestic market challenges [2][8]. Financial Summary - **Revenue and Profit Forecasts**: The projected total revenue for 2025 is 2.634 billion yuan, reflecting a year-on-year decrease of 14.1%. The net profit attributable to shareholders is expected to be 418 million yuan, down 25.5% [4][9]. - **Earnings Per Share (EPS)**: The EPS for 2025 is forecasted at 0.89 yuan, with a price-to-earnings (P/E) ratio of 24 [4][9]. - **Market Capitalization**: The total market capitalization of the company is approximately 9.956 billion yuan [5]. Business Segment Performance - **Chronic Disease Management Testing**: Revenue for this segment was 563 million yuan, down 26.06%. The company is responding to domestic market pressures by launching new products and enhancing its service model [8]. - **Infectious Disease Testing**: Revenue decreased to 379 million yuan, down 21.14%. The company is focusing on maintaining its market position while expanding its product offerings in overseas markets [8]. - **Drug Abuse Testing**: This segment showed a stable growth with revenue of 145 million yuan, up 4.26%, driven by e-commerce strategies [8]. - **Prenatal and Genetic Testing**: Revenue was 138 million yuan, down 11.67%, as the company focuses on product innovation to adapt to market changes [8]. Investment Recommendations - The report suggests that considering the domestic demand for products, the pace of international expansion, and stock compensation expenses, the net profit attributable to shareholders is expected to be 4.2 billion yuan, 4.9 billion yuan, and 5.9 billion yuan for 2025, 2026, and 2027 respectively [8].

Core Viewpoint - Wanfu Biology announced a stock repurchase plan, indicating confidence in its own stock value and commitment to shareholder returns [1] Summary by Category Company Actions - The company will implement a stock repurchase through a special account starting from September 26, 2025 [1] - A total of 13,000 shares will be repurchased, which represents 0.0028% of the company's total share capital [1]

Core Viewpoint - Wanfu Biological (300482.SZ) has initiated a share buyback program, purchasing a total of 13,000 shares, which represents 0.0028% of the company's total equity, at a total cost of 275,729.00 yuan [1] Summary by Category - **Share Buyback Details** - The buyback was conducted on September 26, 2025, through a centralized bidding transaction [1] - The highest and lowest transaction price for the shares was 21.21 yuan per share [1] - **Compliance and Regulations** - The buyback aligns with the company's share repurchase plan and complies with relevant laws and regulations [1]

Group 1 - Company Wanfu Bio announced a stock buyback on September 29, 2025, repurchasing approximately 13,000 shares, which represents 0.0028% of its total share capital, with a total transaction amount of about 280,000 yuan [1] - The maximum and minimum transaction price for the repurchased shares was 21.21 yuan per share [1] - For the year 2024, Wanfu Bio's revenue composition indicates that diagnostic products account for 97.59% of total revenue, while other products account for 2.41% [1] Group 2 - Wanfu Bio's market capitalization is currently 10 billion yuan [2] - The competition in the beverage industry is intensifying, with Farmer's Green Bottle launch leading to a significant market share decline of nearly 5 percentage points for Yibao [2]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-056 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 公司于 2025 年 9 月 26 日首次通过股票回购专用账户以集中竞价交易方式实 施回购，回购公司股份数量为 13,000 股，占公司总股本的 0.0028%，本次回购 股份的最高成交价为 21.21 元/股，最低成交价为 21.21 元/股，成交总金额为 275,729.00 元（不含交易费用）。本次回购符合公司回购股份方案及相关法律法 规的要求。 二、其他说明 公司首次回购股份的时间、回购股份数量及集中竞价交易的委托时段等均符 合《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— —回购股份》的相关规定，具体如下： 1、公司未在下列期间内回购公司股票： （一）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中 ...

注：以上股东的持股数量为合并普通账户和融资融券信用账户后总的持股数量。 二、公司前十名无限售条件股东持股情况 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-055 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 23 日 召开第五届董事会第十四次会议，会议审议通过了《关于回购公司股份方案的议 案》。公司拟使用自有资金以集中竞价交易方式回购公司发行的人民币普通股股 份，用于实施后续员工持股计划或股权激励，具体内容可详见公司于 2025 年 9 月 23 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案暨 回购报告书的公告》（公告编号：2025-054）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回 ...